Allscripts Healthcare Solutions Inc. (MDRX): Price and Financial Metrics

Allscripts Healthcare Solutions Inc. (MDRX): $8.35

0.05 (-0.60%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add MDRX to Watchlist
Sign Up

Industry: Medical - Services

Industry

C

Ranked

#43 of 75

in industry

MDRX Price/Volume Stats

Current price $8.35 52-week high $14.09
Prev. close $8.40 52-week low $5.01
Day low $7.76 Volume 874,900
Day high $9.25 Avg. volume 5,335,856
50-day MA $8.53 Dividend yield N/A
200-day MA $11.53 Market Cap 912.32M

MDRX Stock Price Chart Interactive Chart >

MDRX Stock Summary

  • With a year-over-year growth in debt of -52.38%, VERADIGM INC's debt growth rate surpasses merely 4.72% of about US stocks.
  • Revenue growth over the past 12 months for VERADIGM INC comes in at -39.73%, a number that bests merely 6.45% of the US stocks we're tracking.
  • VERADIGM INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 42.07%, greater than the shareholder yield of 95.61% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to VERADIGM INC, a group of peers worth examining would be VNDA, ALKS, ATEN, SCWX, and DIOD.
  • Visit MDRX's SEC page to see the company's official filings. To visit the company's web site, go to www.allscripts.com.

MDRX Valuation Summary

  • In comparison to the median Healthcare stock, MDRX's EV/EBIT ratio is 23.97% lower, now standing at 11.1.
  • MDRX's price/earnings ratio has moved up 48.5 over the prior 243 months.

Below are key valuation metrics over time for MDRX.

Stock Date P/S P/B P/E EV/EBIT
MDRX 2023-12-29 1.4 1 18.9 11.1
MDRX 2023-12-28 1.4 1 18.9 11.1
MDRX 2023-12-27 1.4 1 18.7 11.0
MDRX 2023-12-26 1.4 1 18.8 11.1
MDRX 2023-12-22 1.4 1 18.9 11.2
MDRX 2023-12-21 1.3 1 18.5 10.8

MDRX Growth Metrics

    Its 5 year cash and equivalents growth rate is now at 103.21%.
  • Its 3 year cash and equivalents growth rate is now at -43.13%.
  • Its 5 year price growth rate is now at -48.3%.
MDRX's revenue has moved down $584,639,000 over the prior 15 months.

The table below shows MDRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 837.191 160.811 60.634
2022-06-30 1,054.541 188.56 62.286
2022-03-31 1,277.357 -10.742 148.238
2021-12-31 1,503.037 -75.428 134.438
2021-09-30 1,389.072 -319.092 774.987
2021-06-30 1,421.83 -322.015 759.349

MDRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MDRX has a Quality Grade of C, ranking ahead of 38.48% of graded US stocks.
  • MDRX's asset turnover comes in at 0.496 -- ranking 62nd of 83 Computers stocks.
  • INVE, CLSK, and DGII are the stocks whose asset turnover ratios are most correlated with MDRX.

The table below shows MDRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.496 0.384 1.040
2021-03-31 0.480 0.384 0.931
2020-12-31 0.481 0.376 0.725
2020-09-30 0.524 0.396 -0.018
2020-06-30 0.534 0.394 -0.025
2020-03-31 0.544 0.397 -0.172

MDRX Price Target

For more insight on analysts targets of MDRX, see our MDRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $17.86 Average Broker Recommendation 1.79 (Moderate Buy)

Allscripts Healthcare Solutions Inc. (MDRX) Company Bio


AllScripts Healthcare Solutions provides clinical, financial, electronic health records (EHR), connectivity, hosting, outsourcing, analytics, patient engagement, and population health products and services in the United States and Canada. It operates in three segments: Clinical and Financial Solutions, Population Health, and Managed Services. The company was founded in 1986 and is based in Chicago, Illinois.


MDRX Latest News Stream


Event/Time News Detail
Loading, please wait...

MDRX Latest Social Stream


Loading social stream, please wait...

View Full MDRX Social Stream

Latest MDRX News From Around the Web

Below are the latest news stories about VERADIGM INC that investors may wish to consider to help them evaluate MDRX as an investment opportunity.

Veradigm Inc. Announces that Nasdaq Hearings Panel has Granted its Continued Listing, Pending Return to Compliance with Nasdaq Filing Requirements

CHICAGO, December 13, 2023--Veradigm Inc. (NASDAQ: MDRX (the "Company")) announced today that it received a decision from the Nasdaq Hearings Panel (the "Panel") granting its request for continued listing on the Nasdaq Capital Market, subject to the Company demonstrating compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rules") on or before February 27, 2024, and certain other conditions, including the achievement of various interim milestones (the "Panel Decision").

Yahoo | December 13, 2023

Veradigm to Enhance Independent Practice Financial Management with AI for Practice Fusion Billing Services

CHICAGO, December 11, 2023--Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that it will now offer a conversational artificial intelligence (AI) agent for Practice Fusion Billing Services, a Veradigm Network solution. Created to quickly answer questions in a conversational format designed to meet client needs, this enhancement will help simplify the billing process and optimize financial management for independent healthcare providers

Yahoo | December 11, 2023

Veradigm Inc. Announces Leadership Transition

CHICAGO, December 08, 2023--Veradigm Inc. (Nasdaq: MDRX) announced today that the Company’s Board of Directors appointed current Chairman, Greg Garrison, as Executive Chairman, and current director, Dr. Shih-Yin ("Yin") Ho, as interim Chief Executive Officer. In addition, Lee Westerfield, who brings more than 25 years of experience as a senior financial executive, most recently serving as Chief Financial Officer at Clearsense, will be serving as Interim Chief Financial Officer. Chief Executive O

Yahoo | December 8, 2023

Veradigm Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q

CHICAGO, November 17, 2023--Veradigm Inc. (Nasdaq: MDRX) announced today that, as expected, it received a notice from Nasdaq indicating that the Company remains noncompliant with Nasdaq Listing Rule 5250(c)(1) because the Company has not filed its Annual Report on Form 10-K for the year ended December 31, 2022 (the "Form 10-K"), Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the "Q1 Form 10-Q"), Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 (the "Q2 Form

Yahoo | November 17, 2023

Returns At Veradigm (NASDAQ:MDRX) Are On The Way Up

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

Yahoo | November 10, 2023

Read More 'MDRX' Stories Here

MDRX Price Returns

1-mo 0.97%
3-mo -15.31%
6-mo -33.57%
1-year -35.77%
3-year -45.99%
5-year -20.78%
YTD -20.40%
2023 -40.53%
2022 -4.39%
2021 27.77%
2020 47.12%
2019 1.82%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!